Volume 8, Issue 2 (Journal of Clinical and Basic Research (JCBR) 2024)
jcbr 2024, 8(2): 28-33 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bola Odegbemi O, Folaranmi Olaniyan M, Abidemi Muhibi M. Impact of tenofovir, lamivudine, and dolutegravir on liver function in HIV-positive individuals in Southern Nigeria. jcbr 2024; 8 (2) :28-33
URL: http://jcbr.goums.ac.ir/article-1-453-en.html
URL: http://jcbr.goums.ac.ir/article-1-453-en.html
1- Medical Laboratory Science Department, Edo State University, Uzairue, Edo State, Nigeria ; Medical Laboratory Science Department, Nigerian Navy Hospital, Warri, Delta State, Nigeria , odegbemi21.odekunle@edouniversity.edu.ng
2- Medical Laboratory Science Department, Edo State University, Uzairue, Edo State, Nigeria
2- Medical Laboratory Science Department, Edo State University, Uzairue, Edo State, Nigeria
Abstract: (491 Views)
Background: Antiretroviral therapy (ART) has transformed HIV management, but concerns regarding liver toxicity persist, particularly with the use of reverse transcriptase inhibitors (RTIs) and integrase strand transfer inhibitors (INSTIs). This study aims to assess the impact of tenofovir/lamivudine/dolutegravir (TLD) therapy on liver function in HIV-positive individuals at a military hospital in southern Nigeria.
Methods: We conducted a cross-sectional study involving 170 participants: 120 HIV-positive individuals on TLD and 50 HIV-negative controls, matched for age, sex, socioeconomic status, and ethnicity. Data were collected through questionnaires and blood sampling. Plasma levels of liver function markers, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutathione S-transferases (GSTs), total protein (TP), and albumin (Alb), were analyzed using relevant biochemical methods. We conducted a statistical analysis using SPSS version 23, with significance set at p < 0.05.
Results: Significant differences were observed in AST, TP, Alb, and GST levels between HIV-positive individuals on TLD and HIV-negative controls. HIV-positive subjects exhibited lower AST and Alb levels but higher TP and GST levels. Further analysis revealed correlations between age, gender, and liver enzymes, highlighting the complex interplay between HIV, liver function, and treatment outcomes.
Conclusion: The results suggested that decreased AST levels may indicate a protective effect of TLD on liver integrity, while ALT activity showed minimal impact. Changes in TP, Alb, and GST levels emphasize the importance of monitoring hepatic function and detoxification pathways in HIV-positive individuals on TLD therapy.
Methods: We conducted a cross-sectional study involving 170 participants: 120 HIV-positive individuals on TLD and 50 HIV-negative controls, matched for age, sex, socioeconomic status, and ethnicity. Data were collected through questionnaires and blood sampling. Plasma levels of liver function markers, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutathione S-transferases (GSTs), total protein (TP), and albumin (Alb), were analyzed using relevant biochemical methods. We conducted a statistical analysis using SPSS version 23, with significance set at p < 0.05.
Results: Significant differences were observed in AST, TP, Alb, and GST levels between HIV-positive individuals on TLD and HIV-negative controls. HIV-positive subjects exhibited lower AST and Alb levels but higher TP and GST levels. Further analysis revealed correlations between age, gender, and liver enzymes, highlighting the complex interplay between HIV, liver function, and treatment outcomes.
Conclusion: The results suggested that decreased AST levels may indicate a protective effect of TLD on liver integrity, while ALT activity showed minimal impact. Changes in TP, Alb, and GST levels emphasize the importance of monitoring hepatic function and detoxification pathways in HIV-positive individuals on TLD therapy.
Article Type: Research |
Subject:
Biochemistry
References
1. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen on hematological parameters, CD4 count, and viral load in people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47):e35910. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. World Health Organization. HIV drug resistance report 2019. 2019. [View at Publisher] [Google Scholar]
3. Benedicto AM, Fuster-Martínez I, Tosca J, Esplugues JV, Blas-García A, Apostolova N. NNRTI and liver damage: Evidence of their association and the mechanisms involved. Cells. 2021;10(7):1687. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Awofala AA, Ogundele OE. HIV epidemiology in Nigeria. Saudi J Biol Sci. 2018;25(4):697-703. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Bassey AE, Miteu GD. A review of current trends in HIV epidemiology, surveillance, and control in Nigeria. Ann Med Surg (Lond). 2023;85(5):1790-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Lwanga SK, Lemeshow S, World Health Organization. Sample size determination in health studies: a practical manual. World Health Organization; 1991. [View at Publisher] [Google Scholar]
7. Wu L, Jin C, Bai S, Davies H, Rao H, Liang Y, et al. The effect of highly active antiretroviral therapy on liver function in HIV-infected pediatric patients with or without hepatitis virus co-infection. J Res Med Sci. 2015;20(2):127-32. [View at Publisher] [PMID] [Google Scholar]
8. Chwiki S, Campos MM, McLaughlin ME, Kleiner DE, Kovacs JA, Morse CG, et al. Adverse effects of antiretroviral therapy on liver hepatocytes and endothelium in HIV patients: An ultrastructural perspective. Ultrastruct Pathol. 2017;41(2):186-95. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Moya-Salazar J, Barrial-Vega M, Arrieta-Calderón R, Contreras-Pulache H. Changes in liver function test levels in HIV patients undergoing highly active antiretroviral therapy (HAART): Longitudinal study in Lima, Peru. Revista de la Facultad de Medicina. 2022;70(1):e86775. [View at Publisher] [DOI] [Google Scholar]
10. Odegbemi OB, Olaniyan MF, Muhibi MA. Hepatic Toxicity Assessment in HIV's Interaction with Reverse Transcriptase and Integrase Strand Transfer Inhibitors at a Military Hospital, Southsouth Nigeria. medRxiv. 2024. [View at Publisher] [DOI] [Google Scholar]
11. Shedrac AE, Haruna M, Gloria EA, Nma YB, Titus EF, Musa DA, et al. Anti-retroviral therapy and serum protein levels in HIV-1 seropositive patients: A five-year retrospective study. medRxiv. 2020. [View at Publisher] [DOI] [Google Scholar]
12. Abubakar MG, Abduljalil MM, Bola-Alaka G, Nasiru YI. Influence of ARVs on Some Biochemical Changes in Liver Non Enzymatic Markers of HIV Positive Patients Attending Specialist Hospital Sokoto, Nigeria. Nigerian Journal of Basic and Applied Science. 2015;23(1):45-50. [View at Publisher] [DOI] [Google Scholar]
13. Abba A, Fokam J, Kamgaing RS, Yimga JF, Ka’e AC, Nka AD, et al. Correlation between the immuno-virological response and the nutritional profile of treatment-experienced HIV-infected patients in the East region of Cameroon. PLoS One. 2021;16(5):e0229550. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Quaye O, Kuleape JA, Bonney EY, Puplampu P, Tagoe EA. Imbalance of antioxidant enzymes activities and trace elements levels in Ghanaian HIV-infected patients. PLoS One. 2019;14(7):e0220181. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Dusingize JC, Hoover DR, Shi Q, Mutimura E, Rudakemwa E, Ndacyayisenga V, et al. Association of Abnormal Liver Function Parameters with HIV Serostatus and CD4 Count in Antiretroviral-Naive Rwandan Women. AIDS Res Hum Retroviruses. 2015;31(7):723-30. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Osakunor DN, Obirikorang C, Fianu V, Asare I, Dakorah M. Hepatic Enzyme Alterations in HIV Patients on Antiretroviral Therapy: A Case-Control Study in a Hospital Setting in Ghana. PLoS One. 2015;10(8):e0134449. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Chory A, Gillette E, Callen G, Wachira J, Sam-Agudu NA, Bond K, et al. Gender differences in HIV knowledge among adolescents and young people in low-and middle-income countries: A systematic review. Front Reprod Health. 2023;5:1154395. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Bernard C, Font H, Diallo Z, Ahonon R, Tine JM, Abouo FN, et al. Effects of Age, Level of Education and HIV Status on Cognitive Performance in West African Older Adults: The West Africa IeDEA Cohort Collaboration. AIDS Behav. 2021;25(10):3316-26. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Aliyu MH, Blevins M, Parrish DD, Megazzini KM, Gebi UI, Muhammad MY, et al. Risk factors for delayed initiation of combination antiretroviral therapy in rural north central Nigeria. J Acquir Immune Defic Syndr. 2014;65(2):e41-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Nkalubo J, Mugaba M, Asasira I, Nakiganda R, Namutebi F, Arnaud NN, et al. Factors associated with readiness to start antiretroviral therapy (ART) among young people (15-24 years) at four HIV clinics in Mulago Hospital, Uganda. Afr Health Sci. 2021;21(4):1603-14. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Mata-Marín JA, Gaytán-Martínez J, Grados-Chavarría BH, Fuentes-Allen JL, Arroyo-Anduiza CI, Alfaro-Mejía A. Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: A concordance cross-sectional study. Virol J. 2009;6:181. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Lapadula G, Costarelli S, Chatenoud L, Castelli F, Astuti N, Giambenedetto SD, et al. Risk of liver enzyme elevation during treatment with ritonavir-boosted protease inhibitors among HIV-monoinfected and HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2015;69(3):312-318. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Mataranyika PA, Kibuule D, Kalemeera F, Kaura H, Rennie TW. Liver enzyme elevations in a cohort of HIV/AIDS patients on first-line antiretroviral therapy in Namibia: Findings and implications. Alexandria Journal of Medicine. 2018;54(1):49-56. [View at Publisher] [DOI] [Google Scholar]
24. Wood S, Won SH, Hsieh HC, Lalani T, Kronmann K, Maves RC, et al. Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era. Open Forum Infect Dis. 2021;8(3):ofab076. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Sung KC, Lee MY, Lee JY, Lee SH, Kim SH, Kim SH. Utility of ALT concentration in men and women with nonalcoholic fatty liver disease: Cohort study. J Clin Med. 2019;8(4):445. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Mennecozzi M, Landesmann B, Palosaari T, Harris G, Whelan M. Hepatotoxicity screening strategies: Comparison of liver enzyme release and NMR-based metabolomics in HepG2 cells and primary rat hepatocytes. Archives of Toxicology. 2012;86(10):1581-1592.
27. Hosen MB, Karmokar NC, Karim MF, Al Mahmud R, Uddin M. Association of AST, ALT, ALB and total protein with beta-thalassemia in Bangladeshi population. Int J Adv Res. 2015;3(1):991-5. [View at Publisher] [Google Scholar]
28. Song X, Zha Y, Liu J, He P, He L. Associations between liver function parameters and poor clinical outcomes in peritoneal dialysis patients. Ther Apher Dial. 2023;27(1):12-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
29. Ocama P, Castelnuovo B, Kamya MR, Kirk GD, Reynolds SJ, Kiragga A, et al. Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS. 2010;21(8):553-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
30. Mazari AMA, Zhang L, Ye ZW, Zhang J, Tew KD, Townsend DM. The multifaceted role of glutathione S-transferases in health and disease. Biomolecules. 2023;13(4):688. [View at Publisher] [DOI] [PMID] [Google Scholar]
31. Belinskaia DA, Voronina PA, Shmurak VI, Jenkins RO, Goncharov NV. Serum albumin in health and disease: Esterase, antioxidant, transporting and signaling properties. Int J Mol Sci. 2021;22(19):10318. [View at Publisher] [DOI] [PMID] [Google Scholar]
32. Qin F, Jiang J, Qin C, Huang Y, Liang B, Xu Y, et al. Liver damage in patients living with HIV on antiretroviral treatment with normal baseline liver function and without HBV/HCV infection: An 11-year retrospective cohort study in Guangxi, China. BMJ Open. 2019;9(4):e023140. [View at Publisher] [DOI] [PMID] [Google Scholar]
33. Igwe CU, Ewuga EE, Ujowundu CO, Onyeocha IO, Onwuliri VA. Serum protein concentration and amino acid profile of HIV/HBV co-infected subjects on HAART in Plateau State, Nigeria. Afr Health Sci. 2022;22(1):418-30. [View at Publisher] [DOI] [PMID] [Google Scholar]
34. Quaye O, Kuleape JA, Bonney EY, Puplampu P, Tagoe EA. Imbalance of antioxidant enzymes activities and trace elements levels in Ghanaian HIV-infected patients. PLoS One. 2019;14(7):e0220181. [View at Publisher] [DOI] [PMID] [Google Scholar]
35. Biały M, Czarnecki M, Inglot M. Impact of Combination Antiretroviral Treatment on Liver Metabolic Health in HIV-Infected Persons. Viruses. 2023;15(12):2432. [View at Publisher] [DOI] [PMID] [Google Scholar]
36. Taramasso L, Lorenzini P, Di Biagio A, Lichtner M, Marchetti G, Rossotti R, et al. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. J Antimicrob Chemother. 2019;74(11):3295-304. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).